Bone morphogenetic proteins (BMP) are naturally occurring proteins in the human body which promotes bone growth. The particular family of proteins is involved in innumerable cellular responses. BMPs are a group of growth factors which are also known as cytokines and metabologens. Such proteins which are already present inside the body can be generated, concentrated and positioned in the spinal area for a spinal fusion to take place. Bone morphogenetic proteins are relegated under the transforming growth attribute beta superfamily. Also, they can create a fusion without the need for any use of the patient’s own bone. Certain BMPs are osteoinductive, which is one of the three prime categories of bone grafts and plays an active role in bone formation and maintenance. Bone morphogenetic proteins (BMP) were first insulated by a scientist named Marshall Urist way back in 1965, who found their ability to infuse the bone and cartilage formation. The proteins sequence in humans might be manufactured synthetically in a consistent and controlled process; this process is commonly referred as recombinant technology, therefore the name "rhBMP" (recombinant human bone morphogenetic protein). Up to now, almost 20 different BMPs have been ascertained, out of which only BMPs 2, 4, 6, 7, and 9 are proved to play a vital role in bone formation. Bone Morphogenetic Protein (BMP) Market suggests that these proteins are highly osteoinductive and should go via stringent preclinical and clinical trials before Premarket Approval (PMA) by the U.S. Food and Drug Administration (FDA).

The key goals of using BMP in spinal fusions are:

  • To generate spinal fusion along with making use of patient’s own bone.
  • To alleviate the necessity for harvesting the patient’s bone from his/her hip and hence preventing the possible side effects and associated complications of the bone harvesting procedure.

Successful growth of a product for use in spinal fusion involves picking the osteoinductive molecule, the amount of the bone morphogenetic protein needed, and the process of delivery, along with conducting consequent clinical and preclinical studies to assess its safety and efficiency. A few of the bone morphogenetic protein as for the products are concerned render for revolutionary therapies in orthopedic practice.